Strides Pharma Science Limited (NSE:STAR)

Strides Pharma Science Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 22, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	73,393	61,675	72,114	25,858	31,121	75,754
Market Cap Growth	14.09%	-14.47%	178.88%	-16.91%	-58.92%	162.55%
Enterprise Value	90,026	81,726	96,197	55,452	54,820	95,516
Last Close Price	796.25	666.19	307.18	111.72	135.22	328.50
PE Ratio	18.47	1.72	-	-	-	28.22
Forward PE	12.83	13.18	26.97	22.79	-	22.19
PS Ratio	1.57	1.35	1.85	0.70	1.01	2.29
PB Ratio	2.62	2.38	3.48	1.19	1.31	2.69
P/TBV Ratio	4.86	4.29	6.75	2.28	2.49	4.52
P/FCF Ratio	18.40	13.96	12.37	-	-	41.18
P/OCF Ratio	10.55	9.01	10.29	58.23	-	15.74
PEG Ratio	-	0.43	0.43	0.43	0.43	0.43
EV/Sales Ratio	1.92	1.79	2.47	1.50	1.79	2.88
EV/EBITDA Ratio	10.31	10.63	17.91	16.30	-	16.07
EV/EBIT Ratio	13.16	13.41	26.66	38.52	-	22.31
EV/FCF Ratio	22.57	18.50	16.50	-	-	51.92
Debt / Equity Ratio	0.66	0.73	1.22	1.39	1.27	0.83
Debt / EBITDA Ratio	2.12	2.37	4.39	8.10	-	3.81
Debt / FCF Ratio	4.62	4.25	4.32	-	-	12.77
Asset Turnover	0.75	0.77	0.62	0.54	0.44	0.50
Inventory Turnover	1.56	1.77	1.68	1.52	1.36	1.43
Quick Ratio	0.47	0.62	0.55	0.59	0.58	0.52
Current Ratio	1.15	1.20	1.03	1.09	0.99	1.03
Return on Equity (ROE)	16.45%	17.58%	-6.78%	-10.13%	-18.25%	9.01%
Return on Assets (ROA)	6.80%	6.41%	3.62%	1.32%	-2.12%	4.06%
Return on Invested Capital (ROIC)	13.06%	11.96%	7.90%	2.86%	-4.69%	8.09%
Return on Capital Employed (ROCE)	18.80%	17.60%	12.20%	3.90%	-6.70%	10.00%
Earnings Yield	5.41%	58.26%	-0.98%	-7.84%	-14.79%	3.54%
FCF Yield	5.44%	7.17%	8.08%	-1.95%	-12.89%	2.43%
Dividend Yield	0.46%	0.60%	0.81%	1.34%	-	0.76%
Payout Ratio	9.28%	0.64%	-	-	-	6.67%
Buyback Yield / Dilution	-0.28%	-1.12%	-1.02%	-0.37%	-0.04%	-0.14%
Total Shareholder Return	0.18%	-0.52%	-0.21%	0.97%	-0.04%	0.62%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.